Focused On-demand Library for Deoxyribonuclease-2-alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Acid DNase; Deoxyribonuclease II alpha; Lysosomal DNase II; R31240_2

Alternative UPACC:

O00115; B2RD06; B7Z4K6; O43910


Deoxyribonuclease-2-alpha, also known as Acid DNase, Lysosomal DNase II, and R31240_2, is pivotal in DNA hydrolysis under acidic conditions, favoring double-stranded DNA. It plays a crucial role in clearing nucleic acids generated through apoptosis, thus preventing autoinflammation. This protein is essential for fetal development and definitive erythropoiesis in fetal liver and bone marrow by degrading nuclear DNA expelled from erythroid precursor cells.

Therapeutic significance:

Deoxyribonuclease-2-alpha is linked to Autoinflammatory-pancytopenia syndrome, a disorder characterized by severe anemia, thrombocytopenia, and a hyperinflammatory state. Understanding the role of Deoxyribonuclease-2-alpha could open doors to potential therapeutic strategies for this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.